INBX - Inhibrx Biosciences Inc.
IEX Last Trade
14.52
0.610 4.201%
Share volume: 145,333
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$13.91
0.61
4.39%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-03-06 | 2023-05-08 | 2023-08-07 | 2023-11-09 | 2024-02-28 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 193.210 M | 164.852 M | 290.875 M | 253.716 M | 213.170 M | 372.733 M | 307.893 M | 288.577 M | |
| Current Assets | 181.623 M | 153.754 M | 280.493 M | 243.777 M | 203.321 M | 363.297 M | 295.358 M | 274.538 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 4.954 M | 7.366 M | 6.371 M | 9.219 M | 10.502 M | 25.639 M | 16.656 M | 19.017 M | |
| Short Term Investments | 4.954 M | 7.366 M | 6.371 M | 9.219 M | 10.502 M | 25.639 M | 16.656 M | 19.017 M | |
| Total Receivables | 284.000 K | 315.000 K | 257.000 K | 304.000 K | 327.000 K | 331.000 K | 778.000 K | 3.038 M | |
| Current Cash | 176.385 M | 146.073 M | 273.865 M | 234.254 M | 192.492 M | 337.327 M | 277.924 M | 252.483 M | |
| Total Non-current Assets | 11.587 M | 11.098 M | 10.382 M | 9.939 M | 9.849 M | 9.436 M | 12.535 M | 14.039 M | |
| Property Plant Equipment | 2.878 M | 2.799 M | 2.501 M | 2.485 M | 2.832 M | 2.864 M | 6.419 M | 6.966 M | |
| Other Assets | 8.709 M | 8.299 M | 7.881 M | 7.454 M | 7.017 M | 6.572 M | 6.116 M | 7.073 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 193.210 M | 164.852 M | 290.875 M | 253.716 M | 213.170 M | 372.733 M | 307.893 M | 288.577 M | |
| Total liabilities | 198.132 M | 199.902 M | 232.818 M | 238.583 M | 237.982 M | 243.138 M | 264.390 M | 277.009 M | |
| Total current liabilities | 24.201 M | 25.426 M | 27.576 M | 32.640 M | 31.329 M | 35.771 M | 56.312 M | 71.870 M | |
| Accounts Payable | 9.247 M | 8.569 M | 8.326 M | 10.916 M | 9.700 M | 7.858 M | 10.954 M | 14.792 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 1.765 M | 1.812 M | 1.860 M | 1.909 M | 1.959 M | 2.011 M | 2.063 M | 5.749 M | |
| Long term debt | 173.931 M | 174.476 M | 205.242 M | 205.943 M | 206.653 M | 207.367 M | 208.078 M | 205.139 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -4.922 M | -35.050 M | 58.057 M | 15.133 M | -24.812 M | 129.595 M | 43.503 M | 11.568 M | |
| Common stock | 39.040 M | 39.071 M | 43.304 M | 43.575 M | 43.642 M | 47.151 M | 54.152 M | 54.554 M | |
| Retained earnings | -296.133 M | -331.458 M | -372.373 M | -421.289 M | -468.341 M | -520.130 M | -613.734 M | -692.444 M |